Cancer Immunotherapy Market

Cancer Immunotherapy Market

Category : Healthcare & Life Sciences Reports | Delivery Format : PDF,PPT | Publisher: Reports and Insights | Pages : XXX

Cancer Immunotherapy Market

Cancer Immunotherapy Market Overview

The report is titled as ‘Cancer Immunotherapy Market: Opportunity Analysis and Future Assessment 2022-2030’. An overview of conceptual frameworks, analytical approaches of the Cancer Immunotherapy market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market. Cancer Immunotherapy market is expected to grow with significant rate in the near future.

The cancer immunotherapy market is estimated to reach at a value of US$ 99.3 Bn by the end of 2022 and expected to reach at a value of US$ 194.5 Bn by 2030 with a significant CAGR of 8.8%.

Cancer Immunotherapy Introduction

An immunotherapy is basically a type of biological therapy that is given for cancer treatment which helps to build the immunity of the individual to fight from cancer. It works by guiding the immune system against the cancer-specific targets by activation of the immune system to impel the target through triggering a response that is proficient to destroy the cancerous cells.

Cancer immunotherapy is more desirable as compared to the old techniques as it provides cancer protection for longer time with less side effects and treatment for comprehensive range of cancers which comprises of melanoma, prostate cancer, breast cancer, colorectal cancer, lung cancer, head & neck cancer, and more. There are various types of immunotherapies used for cancer treatment such as, T-cell transfer therapy, Immune checkpoint inhibitors, Monoclonal antibodies, Vaccines treatment and Immune system modulators.

One of the primary factors that is boosting the demand of cancer immunotherapy is the rising incidences of the cancers among the population. Moreover, the increasing usage of cancer immunotherapy for melanoma therapeutics contributing to the manufacturing of novel products, ample number of FDA approvals as well as the progression in research and development sector which is further increasing the growth of cancer immunotherapy market in the forthcoming future.

Cancer Immunotherapy Market Segmentation

The cancer immunotherapy market is segmented on the basis of product type, application, end user, and region

By Product Type

Monoclonal Antibodies

Cytokines & Immunomodulators

Immune Checkpoint Inhibitors (ICI)

PD-1 inhibitors

PD-L1 inhibitors

Oncolytic Viral Therapies


By Application

Lung Cancer

Breast Cancer

Colorectal Cancer


Prostate Cancer

Head & Neck Cancer


By End User



Cancer Research Centers

By Region

North America

Latin America

Asia Pacific


Middle East


Cancer Immunotherapy Market Key Players

Some of the key participating players in cancer immunotherapy market are:

Amgen Inc.


F. Hoffmann-La Roche Ltd

Bristol-Myers Squibb Company

Merck & Co., Inc.

Seattle Genetics Inc.

Celgene Corporation

Eli Lilly and Company

Novartis AG

Pfizer, Inc.

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth includes (but not restricted to):

New product designs and launches

Current product compliance


Concerns for use of Cancer Immunotherapy

Advantages of Cancer Immunotherapy

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to take informed decision.

A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s product sales, previous growth rates and market expansion plans are considered to generate market share in the market.

To learn more about this report, request a free sample copy

Select License Type

Frequently Asked Questions

The cancer immunotherapy market is estimated to reach at a value of US$ 99.3 Bn by the end of 2022 and expected to reach at a value of US$ 194.5 Bn by 2030 with a significant CAGR of 8.8%.

The base year for the report is 2021 in cancer immunotherapy market.

The global cancer immunotherapy market is segmented on the basis of product type, application, end user, and region

Amgen Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Merck & Co., Inc., Seattle Genetics Inc., Celgene Corporation, Eli Lilly and Company, Novartis AG and Pfizer, Inc.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy